Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells

Clinical and Experimental Immunology

Volumn 182, Issue 2, 2015, Pages 220-229

  Pato, A ^a,b   Eisenberg, G ^b   Machlenkin, A ^b   Margalit, A ^a,c   Cafri, G ^a,d,e   Frankenburg, S ^b   Merims, S ^b   Peretz, T ^b   Lotem, M ^b   Gross, G ^a,c  

^a MIGAL Galilee Technology Center Kiryat   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL HAI COLLEGE   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD8 T lymphocytes; Constitutively active TLR 4; MRNA electroporation; Tumour infiltrating lymphocytes

Indexed keywords

CD137 ANTIGEN; CD69 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; LECTIN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; EFFECTOR CELL; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MELANOMA; MELANOMA CELL LINE; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; CELL CULTURE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; K-562 CELL LINE; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOKINES; CYTOKINES; ELECTROPORATION; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; K562 CELLS; LECTINS, C-TYPE; LYMPHOCYTES, TUMOR-INFILTRATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944168983     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12688     Document Type: Article

References (58)

1. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014; 257:56-71.
2. Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev 2014; 257:250-63.
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81.
4. Wu R, Forget M, Chacon J et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012; 18:160-75.
5. Itzhaki O, Levy D, Zikich D et al. Adoptive T-cell transfer in melanoma. Immunotherapy 2013; 5:79-90.
6. Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013; 20:289-97.
7. Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344:641-5.
8. Merhavi-Shoham E, Haga-Friedman A, Cohen CJ. Genetically modulating T-cell function to target cancer. Semin Cancer Biol 2012; 22:14-22.
9. Zhang L, Morgan RA. Genetic engineering with T cell receptors. Adv Drug Deliv Rev 2012; 64:756-62.
10. Eshhar Z, Waks T, Gross G. The emergence of T-bodies/CAR T cells. Cancer J 2014; 20:123-6.
11. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015; 263:68-89.
12. Cieri N, Mastaglio S, Oliveira G, Casucci M, Bondanza A, Bonini C. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol Rev 2014; 257:165-80.
13. Torikai H, Reik A, Liu P et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012; 119:5697-705.
14. Torikai H, Reik A, Soldner F et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 2013; 122:1341-9.
15. Linnemann C, Mezzadra R, Schumacher TNM. TCR repertoires of intratumoral T-cell subsets. Immunol Rev 2014; 257:72-82.
16. Gajewski TF, Woo S, Zha Y et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25:268-76.
17. Wu RC, Liu S, Chacon JA et al. Detection and characterization of a novel subset of CD8 +CD57+T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res 2012; 18:2465-77.
18. Reynolds JM, Dong C. Toll-like receptor regulation of effector T lymphocyte function. Trends Immunol 2013; 34:511-9.
19. Ozinsky A, Underhill DM, Fontenot JD et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97:13766-71.
20. Wilgenhof S, Van Nuffel AMT, Corthals J et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011; 34:448-56.
21. Cafri G, Amram E, Rinott G et al. Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. Int Immunol 2011; 23:453-61.
22. Machlenkin A, Uzana R, Frankenburg S et al. Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res 2008; 68:2006-13.
23. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26:332-42.
24. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34.
25. Komai-Koma M, Gilchrist DS, Xu D. Direct recognition of LPS by human but not murine CD8+ T cells via TLR4 complex. Eur J Immunol 2009; 39:1564-72.
26. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 2004; 101:3029-34.
27. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65:333-47.
28. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44.
29. Treisman J, Hwu P, Minamoto S et al. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 1995; 85:139-45.
30. Heemskerk B, Liu K, Dudley ME et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19:496-510.
31. Kerkar SP, Muranski P, Kaiser A et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010; 70:6725-34.
32. Pegram HJ, Lee JC, Hayman EG et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133-41.
33. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011; 71:5697-706.
34. Zhang L, Kerkar SP, Yu Z et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011; 19:751-9.
35. Chinnasamy D, Yu Z, Kerkar SP et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83.
36. Rowley J, Monie A, Hung CF, Wu TC. Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol 2009; 39:491-506.
37. Hwu P, Yannelli J, Kriegler M et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α cDNA for the gene therapy of cancer in humans. J Immunol 1993; 150:4104-15.
38. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175:7046-52.
39. Huang J, Khong HT, Dudley ME et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28:258-67.
40. Powell JDJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105:241-50.
41. Shen X, Zhou J, Hathcock KS et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007; 30:123-9.
42. Tran KQ, Zhou J, Durflinger KH et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008; 31:742-51.
43. Besser MJ, Shapira-Frommer R, Treves AJ et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother 2009; 32:415-23.
44. Xu X, Tang Y. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014; 343:172-8.
45. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48.
46. Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6.
47. 3 and GM-CSF. J Immunol 2012; 188:6389-98.
48. Hernandez-Chacon JA, Li Y, Wu RC et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34:236-50.
49. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73.
50. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17.
51. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
52. Zhao Y, Zheng Z, Cohen CJ et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006; 13:151-9.
53. Birkholz K, Hombach A, Krug C et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther 2009; 16:596-604.
54. Thomas S, Klobuch S, Besold K et al. Strong and sustained effector function of memory- versus naive-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy. Eur J Immunol 2012; 42:3442-53.
55. Beatty GL, Haas AR, Maus MV et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2014; 2:112-20.
56. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 2013; 24:717-27.
57. Krug C, Wiesinger M, Abken H et al. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother 2014; 63:999-1008.
58. Kobold S, Wiedemann G, Rothenfußer S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy 2014; 6:1085-95.